362 results about "Sodium Chloride Injection" patented technology

The invention relates to a kit for processing human marrow, cord blood and peripheral blood stem cells and a stem cell processing method. The kit radically solves the problems of high manufacture cost, low cell activity, indefinite reaction of markers in a human body, mobilizing agent injection causing patient pain, long obtainment time, complication, clinical unsuitability, and the like in the prior cell separation technology. The invention has the technical scheme that the kit comprises the following three reagents: (1) a diluent comprising 0.9 percent of sodium chloride injection or PBS solution, (2) a precipitator comprising 6 percent of hydroxyethyl starch or 0.2-1 percent of methyl cellulose and (3) a separating solution which has the density of 1.074-1.076 and is prepared by saccharosan and diatrizoate. The kit is easy to store and transport and convenient and rapid to use and can be produced in industrialization.

The invention relates to an ibuprofen injection and a preparation method thereof. The ibuprofen injection is characterized in that the concentration of ibuprofen in the injection is 100mg/ml, arginine is used as a cosolvent, and the molar ratio of the arginine to the ibuprofen is greater than or equal to 1:1. The invention also provides a method for preparing the injection. The prepared injection which has good dissolvability is added into a 0.9% sodium chloride injection or a 5% glucose injection, the concentration of the ibuprofen is 4mg/ml or less than 4mg/ml, and the solution is clear and is stabilized for a long time. The ibuprofen injection is suitable for intravenous drip for patients for whom the oral administration is not suitable.

The invention provides a vinpocetin containing high-capacity sodium chloride injection and a preparation method thereof, aiming at solving the problems that vinpocetin is mainly applied to middle aged and elderly patients, high-capacity glucose injection contains massive glucose and is not beneficial to treating patients suffering from diabetes at the same time. The invention has the key point that the injection is mainly composed of vinpocetin, osmotic pressure regulator, cosolvent and pH value regulator. The vinpocetin high-capacity sodium chloride injection of the invention has high bioavailability and stable quality, is convenient to use and is applicable to treatment of patients suffering from neurologic disease caused by cerebral circulation restriction, especially the patients suffering from diabetes at the same time.

The invention relates to a stable moxifloxacin hydrochloride injection, which concretely contains moxifloxacin hydrochloride and xylitol. The injection can be in the forms of an injection, a transfusion and a freeze-drying powder injection. By the adoption of the stable moxifloxacin hydrochloride injection, stability of moxifloxacin hydrochloride-related substances, solution color, insoluble microparticles and the like during preparation, storage and usage processes of a moxifloxacin hydrochloride glucose or moxifloxacin hydrochloride sodium chloride injection in the present products or technologies is improved. The preparation process has no demanding requirements on equipment and is easy for industrial production.

The invention provides a ropivacaine hydrochloride sodium chloride injection and a preparation method thereof. The method comprises the process steps of: burdening, carbon adsorption, rough filtering, fine filtering, filling, sterilizing, lamp detecting, packing and the like. The prepared ropivacaine hydrochloride sodium chloride injection has a definite medicinal effect and high safety; the testresult of each index in a stability test is accordant with specifications, and the defects of the requirement of repeated injection, inconvenience in using, easiness in increasing secondary pollutionby freeze-dried powder and the like existing in a ropivacaine water injection are overcome; the ropivacaine hydrochloride sodium chloride injection is particularly suitable for a patient using an analgesia pump; during use in a large volume, an instant stable concentration is kept for a medicinal liquid, so that a remarkable postoperative analgesic effect is achieved, and the requirement of an opioid medicament is remarkably lowered; and moreover, the effect can be enhanced rapidly by administrating in a self-pressing way.

The invention discloses a cryopreserving solution for clinical-grade CAR-T cryopreservation and capable of being directly reinfused through intravenous infusion. The cryopreserving solution comprisesthe following raw materials: dimethyl sulfoxide, a glycerol fructose sodium chloride injection, an invert sugar electrolyte injection, a dextran 40 glucose injection, a hydroxyethyl starch 130/0.4 electrolyte injection, a vitamin C injection, a human serum albumin injection and a 0.9 % sodium chloride injection; the cryopreserving solution has the pH value of 6.8-7.0. When a formula for the clinical-grade CAR-T cryopreservation and capable of being directly reinfused through the intravenous infusion is used for cryopreserving CAR-T cells, the thawed cells and the thawed cryopreserving solutiondo not need centrifugation, resuspension, fluid exchange and other processes and can be directly reinfused through the intravenous infusion, so that the loss of cell varieties due to pollution in-vitro repeated proliferation of the CAR-T cells, or changes of cell morphologies and cell functions are effectively avoided, medical equipment can be also significantly simplified and the workload of medical workers can be reduced.

A liquid sodium chloride injection of isosorbide mononitrate for treating coronary heart disease and angina pectoris is prepared from isosorbide mononitrate and sodium chloride. It can quickly take its high curative effect.

The invention belongs to the technical field of pharmaceutical preparations, in particular to a compound monoammonium glycyrrhizinate S pharmaceutical composition and a method for preparing a high-capacity injection. The composition is a compound monoammonium glycyrrhizinate S sodium chloride injection. The injection is characterized by comprising the following components: 40-160g of monoammonium glycyrrhizinate S, 30-120g of cysteine hydrochloride, 400-1,600g of glycine, 40-160g of anhydrous sodium sulphite, 4-16g of sodium citrate, 900-1,800g of sodium chloride, a proper amount of sodium hydroxide and 100-200L of water for injection. The high-capacity injection is more stable and safer.

The invention provides a glucose and sodium chloride injection, which is prepared from glucose 50g (or 100g, 200g, 500g), sodium chloride 9g and balancing water for injection to 1000ml through mixing, inspecting, encapsulating, sterilizing, lamp checking and packaging.

The invention provides a preparation method of high-purity breviscapinun material used by a breviscapinun injection. The method comprises the preparation steps of: carrying out dissolving, alcohol precipitation, acid precipitation, ultrafitration and the like on the breviscapinun to obtain the high-purity breviscapinun material. The purity of the high-purity breviscapinun material can achieve more than 98 percent by detection through high performance liquid chromatography, and the high-purity breviscapinun material can be used for preparing large-capacity injection such as breviscapinun sodium chloride injection or breviscapinun glucose Injection.

The invention discloses a carbazochrome sodium sulfonate sodium chloride injection and a preparation method thereof. The product quality and stability are significantly improved by adding a stabilizer A and a stabilizer B, and controlling the pH value and the sterilization condition in the production process. The carbazochrome sodium sulfonate sodium chloride injection is prepared by adopting the formula, and the problems that the carbazochrome sodium sulfonate sodium chloride injection in the prior art cannot tolerate sterilization of which F0 is greater than or equal to 8, and the product is poor in stability in the production and storage processes are solved.

The invention discloses a pre-diluted vacuum blood collection tube, which comprises a tube body and a tube plug, wherein a tube cap is arranged at the outer side of the tube plug; the tube body, which is sealed, is under a vacuum state; scale marks, which are used for marking capacity of the tube body, are arranged on the outer wall of the tube body; scale values, indicated by the scale marks, range from 9mL to 10.5mL, and a minimum division value is 0.1mL; and 9mL of sodium chloride injection or compound electrolyte injection is contained in the tube body. The invention also discloses a method for measuring platelet number in a patient with EDTA-dependent pseudo-thrombocytopenia with the application of the pre-diluted vacuum blood collection tube. The pre-diluted vacuum blood collection tube provided by the invention is simple in structure; the pre-diluted vacuum blood collection tube is designed with the precise scale marks; venous blood is diluted by liquid which is free from an anticoagulation, so that autologous antigen in an anticoagulation-induced and activated platelet membrane glycoprotein GPIIb structure, and a purpose of inhibiting platelet aggregation is achieved; and the pre-diluted vacuum blood collection tube, through a mode of vacuum blood collection, simplifies operations and avoids pollution, caused by open blood collection, to operators and environment.

The invention provides a high-capacity bromhexine hydrochloride sodium chloride injection composition. The bromhexine hydrochloride sodium chloride injection provided by the invention is prepared from bromhexine hydrochloride, sodium chloride, tartaric acid, glacial acetic acid and injection water. The bromhexine hydrochloride sodium chloride injection provided by the invention has the advantages of low content of related substances, high stability and the like.

An adetphos injecting liquid for intravenous injection and its preparation method. The medical carriers include buffering agents such as phosphate, carbonate, acetate and citrate solution, as well aswater for injecting. The another object of the invention is the preparation method of the adetphos injecting liquid. It comprises preparing a concentrated solution of the stabilizing agent, preparinga concentrated adetphos solution, preparing a concentrated solution of buffering agents, preparing injecting liquid of adetphos and sodium chloride. The adetphos injecting liquid is stable, avoid cross infection, and improve the clinical application of adetphos.

The invention relates to the novel administration methods of traditional medicinal injection for treating coronary atherosclerotic heart disease, thrombolysis in myocardial infarction, center syrup liquid chorioretintis and children's pneumonia, and the process for its preparation. The invention is prepared from pubescent holly root, freeze-dried powder, germ-free powder, 5% glucose injection, 5% sodium chloride injection through extracting with water, decompression concentrating, alcohol depositing, filtrating, adjusting pH, filtrating, charging water for injection into the filter liquor. A novel administration method of intra-vascular injection is provided.

The invention discloses a glycerin fructose sodium chloride injection and a preparation process thereof. The glycerin fructose sodium chloride injection is prepared by the following step: preparing 50-150 parts of glycerinum, 5-15 parts of sodium chloride and 10-100 parts of fructose for injection at a low temperature and carrying out ultrafiltration, wherein low temperature refers to the temperature at 30-60 DEG C. According to the glycerin fructose sodium chloride injection, a new technology is used. By adopting a new low-temperature preparation and ultrafiltration technology, no auxiliaries and active carbon are added in the preparation process, so that the problem that fructose is unstable (5-hydroxymethylfurfural is generated) and the problem on safety of residues of active carbon are solved, and the clinical potential safety hazards are eliminated.

The invention relates to isosorbide mononitrate sodium chloride injection which belongs to the field of medical preparation. The isosorbide mononitrate sodium chloride injection is prepared from 10-40mg of isosorbide mononitrate, 450-1800mg of sodium chloride, an amount of pH regulator which regulates the pH to 4.0-7.0 and water for injection, wherein the volume of the water for injection is fixed to 100ml. The isosorbide mononitrate sodium chloride injection has high stability and simple preparation process.

The invention relates to a children pharmaceutical composition containing ceftriaxone sodium, namely a pharmaceutical combined preparation containing ceftriaxone sodium and a low-sodium carrier infusion solution, and particularly relates to a combined package. The children pharmaceutical composition comprises ceftriaxone sodium for injection and the low-sodium carrier infusion solution. The low-sodium carrier infusion solution contains a glucose and sodium chloride injection (15-200):1, a glucose and sodium chloride potassium chloride injection (15-200):1: (0-1) and the like. Compared with a mixture of ceftriaxone sodium and the low-sodium carrier infusion solution, the children pharmaceutical composition has the advantages that clinical application steps are simplified, clinical risks generated because kidneys of children are not developed to be mature and overmuch sodium in blood cannot be metabolized are reduced, and the clinical application quality and safety performance of children medication are improved.

The invention discloses a glycerin fructose sodium chloride injection and a preparation process thereof. According to the invention, the preparation method of the glycerin fructose sodium chloride injection comprises the following steps: preparing 50-150 parts of glycerin, 5-15 parts of sodium chloride and 10-100 parts of injection fructose by weight at a low temperature; and ultra-filtering a prepared product, wherein the low temperature is 30-60 DEG C. As the glycerin fructose sodium chloride injection disclosed by the invention is prepared by using a new technology and using a novel low temperature preparation and ultrafiltration technology, and any auxiliary material and active carbon are not needed in the preparation process, the instability problem of the fructose (5-hydroxymethyl furfural is generated) and the safety problem of active carbon residue are solved, and clinical potential safety hazards are eliminated.

The invention relates to moxifloxacin hydrochloride sodium chloride injection and a preparation method thereof, and aims at overcoming the shortage of the prior art, solving the problem that the detection result shows that moxifloxacin content is inconsistent in final moxifloxacin hydrochloride sodium chloride injection in the background technology, as well as solving the problem of complexity of the existing process. The preparation method, provided by the invention, is a novel preparation method capable of avoiding product pollution and ensuring the safety and stability of the product quality. The moxifloxacin hydrochloride sodium chloride injection is characterized by containing 0.05 to 0.3% (w/v) of moxifloxacin based on the amount of moxifloxacin, 0.8 to 0.85% (w/v) of sodium chloride, and water of injection, wherein the concentrated preparation volume is 70 to 80%, 0.025 to 0.1% (w/v) of activated carbon is added and agitated for 10 to 30 minutes, and hydrochloric acid or sodium hydroxide is used as a pH modifier. The preparation method is simple and feasible in process and can be used for producing medicines for treating or preventing human or animal bacterial infection.

The invention provides a method for preparing levofloxacin hydrochloride sodium chloride injection. By researching a liquid medicine preparation method, medicinal charcoal pretreatment and a terminal sterilization process, product quality is ensured by the aid of technologies of a concentrated solution and diluted solution method, charcoal slurry preparation from medicinal charcoal, water bath sterilization and the like, production is facilitated, obtained finished products have higher stability, so that the storage life of the finished products can be prolonged, and clinical use effects are better.

The invention relates to moxifloxacinhydrochloride sodium chloride injection. The injection comprises the following components in percentage by weight/volume: 0.03 to 1 percent of moxifloxacinhydrochloride, 0.01 to 3 percent of weak acid, 0.01 to 3 percent of salt of weak acid, 0.01 to 3 percent of phosphoric acid, 0.01 to 3 percent of amino acid or phosphate and 0.65 to 0.95 percent of sodium chloride.